Home > Insider Trading > Filing (0001140361-19-018090)

Filing Details

Accession Number:: 0001140361-19-018090
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-10-07 19:39:20
Reporting Period:: 2019-10-07

Accepted Time:: 2019-10-07 19:39:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1781983	Aprea Therapeutics Inc.	APRE	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1589095	Versant Affiliates Fund V, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	No	No
1589097	Versant Venture Capital V, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	No	No
1589098	Versant Ophthalmic Affiliates I, L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	No	No
1612235	Versant Venture Capital V (Canada), Lp	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	No	No
1619297	Versant Ventures V Gp-Gp (Canada), Inc.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	No	No
1619298	Versant Ventures V, Llc	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	No	No
1716490	Versant Ventures V (Canada), L.p.	One Sansome Street Suite 3630 San Francisco CA 94104	No	No	No	No
1786141	R.l. S.a Luxco V Versant	15 Boulevard F.w. Raiffeisen 2411 Luxembourg N4 L-2411	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-10-07	1,993,658	$0.00	2,006,328	No	4	C	Direct
Common Stock	Acquisiton	2019-10-07	512,995	$0.00	2,519,323	No	4	C	Direct
Common Stock	Acquisiton	2019-10-07	333,333	$15.00	333,333	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Direct
No	4	P	Indirect	See footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Convertible Preferred Stock	Disposition	2019-10-07	1,993,658	$0.00	1,993,658	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2019-10-07	512,995	$0.00	512,995	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Shares"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.
These Shares and Preferred Stock are directly held by Versant V Luxco S.a r.l.
Versant V Luxco S.a r.l. is majority owned by Versant Venture Capital V, L.P. and minority owned by Versant Ophthalmic Affiliates Fund I, L.P., Versant Affiliates Fund V, L.P. (together with Versant Venture Capital V, L.P. and Versant Ophthalmic Affiliates Fund I, L.P, the "Versant Funds") and Versant Venture Capital V (Canada) LP ("Versant Canada"). Versant Ventures V, LLC ("Ventures V") is the general partner of each of the Versant Funds. Versant Ventures V GP-GP (Canada), Inc. is the general partner of Versant Ventures V (Canada), L.P., which is the general partner of Versant Canada. Each of the Versant Funds, Versant Canada, Versant Ventures V (Canada), L.P., Versant Ventures V GP-GP (Canada), Inc. and Ventures V may be deemed to indirectly beneficially own the shares beneficially owned by Versant V Luxco S.a r.l., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
These Shares are directly held by Versant Vantage I, L.P. Versant Vantage I GP-GP, LLC is the general partner of Versant Vantage I GP, L.P., which is the general partner of Versant Vantage I, L.P. Each of Versant Vantage I GP-GP, LLC and Versant Vantage I GP, L.P. may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, L.P., but each disclaims such beneficial ownership except to the extent of its pecuniary interest therein.
Samuel D. Colella ("Colella"), William J. Link ("Link"), Bradley Bolzon, Ph.D ("Bolzon"), Kirk G. Nielsen ("Nielsen"), Thomas Woiwode ("Woiwode"), Jerel C. Davis ("Davis") and Robin L. Praeger ("Praeger") are managing directors of Ventures V. Bolzon, Woiwode, Davis, Praeger, and Clare Ozawa ("Ozawa") are managing directors of Versant Vantage I GP-GP, LLC. Each of Colella, Link, Bolzon, Nielsen, Woiwode, Praeger, Davis and Ozawa disclaim beneficial ownership of the Shares reported herein, except to the extent of his or her pecuniary interest therein.